Abstract:Abnormal expansion of the polyglutamine (polyQ) tract in ataxin‐2 (Atx2) triggers protein aggregation that may consequently lead to SCA2 disease. Either normal or polyQ‐expanded Atx2 can sequester the mTORC1 component Raptor into aggregates, while its polyQ tract and N‐terminal region are responsible for the specific interaction and sequestration. This sequestration process suppresses mTORC1 activity and induces autophagy, which is implicated in the pathologies of SCA2 and other polyQ‐associated diseases. Ataxin‐2 (Atx2) is a polyglutamine (polyQ) protein, in which abnormal expansion of the polyQ tract can trigger protein aggregation and consequently cause spinocerebellar ataxia type 2 (SCA2), but the mechanism underlying how Atx2 aggregation leads to proteinopathy remains elusive. Here, we investigate the molecular mechanism and cellular consequences of Atx2 aggregation by molecular cell biology approaches. We have revealed that either normal or polyQ‐expanded Atx2 can sequester Raptor, a component of mammalian target of rapamycin complex 1 (mTORC1), into aggregates based on their specific interaction. Further research indicates that the polyQ tract and the N‐terminal region (residues 1–784) of Atx2 are responsible for the specific sequestration. Moreover, this sequestration leads to suppression of the mTORC1 activity as represented by down‐regulation of phosphorylated P70S6K, which can be reversed by overexpression of Raptor. As mTORC1 is a key regulator of autophagy, Atx2 aggregation and sequestration also induces autophagy by upregulating LC3‐II and reducing phosphorylated ULK1 levels. This study proposes that Atx2 sequesters Raptor into aggregates, thereby impairing cellular mTORC1 signaling and inducing autophagy, and will be beneficial for a better understanding of the pathogenesis of SCA2 and other polyQ diseases.

The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease

Functional implications of paralog genes in polyglutamine spinocerebellar ataxias

Ataxin-2: a powerful RNA-binding protein

ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3

Spinal cord phosphoproteome of a SCA2/ALS13 mouse model reveals alteration of ATXN2-N-term SH3-actin interactome and of autophagy via WNK1-MYO6-OPTN-SQSTM1

ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

ALS-associated genes in SCA2 mouse spinal cord transcriptomes

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1

Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets

Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways

Structured and disordered regions of Ataxin-2 contribute differently to the specificity and efficiency of mRNP granule formation

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

Ataxin‐2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling

A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion

Toward understanding Machado–Joseph disease

Ataxin-2 polyglutamine expansions aberrantly sequester TDP-43 ribonucleoprotein condensates disrupting mRNA transport and local translation in neurons

Determining The Fate Of Neurons In Sca3: Atx3, A Rising Decision Maker In Response To Dna Stresses And Beyond